Minoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...
Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data.
Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...
Pediatric Investigational Plan (PIP) for leriglitazone in X-ALD approved by EMA, allowing to file Marketing Authorization Application (MAA) in Europe based on NEXUS